Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
Stryker Q3 2026 Earnings Analysis
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Stryker's third quarter 2026 results. There's a lot to unpack here—an orthopaedics slowdown, a big robotics announcement, and a CEO transition all in one call.
But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Right, and this one's actually a pretty meaty transcript, Alex. It's Kevin Lobo's last earnings call as CEO—57 quarters, which is a wild number—before he hands the reins to Spencer Stiles. So there's a bit of a "passing the torch" energy, but also some real business headwinds to address.
**ALEX:** Let's start with the numbers. Stryker posted organic sales growth of 7.7% for the quarter. Adjusted EPS came in at $3.52, up about 10% year-over-year. On the surface, that sounds pretty solid.
**JORDAN:** It does, but the devil's in the segment details. MedSurg and Neurotechnology grew 9.1%—that's the strong part of the story. Endoscopy was up double digits in the U.S., Medical grew 10%, Vascular grew 13%. But Orthopaedics—their bread-and-butter joint replacement business—only grew 5.9%, and within that, U.S. Knees were up just 1.3% and U.S. Hips actually declined slightly.
**ALEX:** And that's really the headline story here, right? Management flagged a genuine market slowdown in U.S. hip and knee procedures.
**JORDAN:** Exactly. Kevin Lobo was pretty candid about it. He pointed to patient affordability issues—higher deductibles, higher premiums—plus an uptick in insurance pre-authorization denials that's delaying patients from getting procedures done. He estimated the overall hip-and-knee market is now growing around 2.5%, which is a notable step down from the 5-6% range we've seen in recent years.
**ALEX:** And it wasn't just market softness—Stryker also admitted they're not winning share at their historical pace.
**JORDAN:** Right, and they were refreshingly honest about why. 2026 has been a messy year operationally. There was the cyber incident back in Q1, and then in July they completed their final SAP system implementation within Orthopaedics. Management said that actually delayed their visibility into real-time market conditions—they didn't fully grasp the slowdown until September, during an investor conference.
**ALEX:** That's a pretty candid admission—basically saying "we were flying partially blind on our own numbers."
**JORDAN:** It is. And it ties into why new products like Mako RPS and Triathlon Gold haven't scaled as fast as hoped—not a product problem, they said, but a commercial execution and distraction problem. The silver lining: they're bringing a power hip impaction tool to market next year, which fills a real gap in their hip portfolio and could help with competitive conversions.
**ALEX:** Let's talk strategy, because there were two notable moves this quarter. First, they closed the acquisition of ZuriMED, which brings fiber-locker technology for rotator cuff repair—plugging nicely into their existing shoulder and sports medicine business.
**JORDAN:** The bigger one, though, is the strategic investment in CMR Surgical. Stryker is becoming the exclusive U.S. sales agent for CMR's Versius soft-tissue robotic platform. This is interesting because Lobo was very clear this is intentionally structured to be low-risk—they're an investor and commercial partner for now, not an outright owner.
**ALEX:** Why not just buy the whole thing?
**JORDAN:** Lobo explained it well—he called it "derisking." Developing a soft-tissue robot from scratch is expensive and uncertain, and this lets Stryker test c
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet